Diethylcarbamazine as potential treatment of COVID-19 lung fibrosis

Diethylcarbamazine, the antiparasitic drug, also possesses anti-inflammatory and immunomodulatory activities. The anti-fibrotic activity of diethylcarbamazine makes it a potential candidate to treat coronavirus disease 2019 (COVID-19)-related pulmonary fibrosis. Experimental and clinical studies sho...

Descripción completa

Detalles Bibliográficos
Autores principales: Medina-De la Garza, Carlos Eduardo, Salvador Flores-Torres, Armando, García-Hernández, Marisela, de los Ángeles Castro-Corona, María
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788098/
https://www.ncbi.nlm.nih.gov/pubmed/35095174
http://dx.doi.org/10.1016/j.mehy.2022.110774
Descripción
Sumario:Diethylcarbamazine, the antiparasitic drug, also possesses anti-inflammatory and immunomodulatory activities. The anti-fibrotic activity of diethylcarbamazine makes it a potential candidate to treat coronavirus disease 2019 (COVID-19)-related pulmonary fibrosis. Experimental and clinical studies should assess this possible effect.

Ejemplares similares